A Pivotal Study to Evaluate Guardian™ Connect CGM System Performance in China

• ClinicalTrials.gov Identifier: NCT03710083
• Recruitment Status: Completed
• First Posted: October 17, 2018
• Results First Posted: August 21, 2020
• Last Update Posted: September 9, 2020
• Sponsor: Medtronic Diabetes
• Information provided by (Responsible Party): Medtronic Diabetes

Study Description

Brief Summary:

The purpose of this study is to demonstrate the performance and safety of the Guardian™ Sensor (3) over 170 hours (7 days) when inserted in the abdomen used in subjects age 14 - 75 years with the Guardian™ Connect System.

Condition or disease	Intervention/treatment	Phase
Diabetes Mellitus	Device: Guardian™ Sensor (3)	Not Applicable

Detailed Description:

This study is a multi-center, prospective single-arm design without controls. Up to 72 subjects will be enrolled in order to have approximately 60 subjects complete the study. Three investigational centers in China will be used during this study.

During the study, each subject will be randomly assigned to one day of the Yellow Springs Instrument (YSI™*) frequent sample testing (FST) (Day 1, 3-5, or 7).Subjects will wear two Guardian™ Sensor (3)s each connected to a Guardian™ Connect transmitter for approximately 7 days (one which will be paired to the Guardian Connect app and the other will function as a glucose recorder.).

The Guardian Sensor (3)s will be worn in the abdomen area and self-inserted by the subject on same side or opposite sides.

On the evening prior to FST, subjects will be asked to fast for approximately 12 hours and adjust their insulin and medications according to routine care (for example as they would do for fasting lipid panel). Subjects may fast for shorter period of time based on investigator discretion.

The subject should be in fasting status upon arrival hospital to start FST process. The feeding protocol may be modified based on investigator discretion. The duration of FST will be approximately 7 hours.

During the study, subjects will continue with their current diabetes regimen independent of the study devices. Subjects will be instructed by the investigational center that they are not to use the study devices (except for the CONTOUR™* study meter) for the management of their diabetes. The CONTOUR™* study meter may be used for treatment decisions and calibration of Guardian™ Sensor (3).

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 72 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Pivotal Study to Evaluate Guardian™ Connect CGM System Performance in China
• Actual Study Start Date: February 28, 2019
• Actual Primary Completion Date: July 25, 2019
• Actual Study Completion Date: July 25, 2019

Arms and Interventions

Arm	Intervention/treatment
Experimental: Study arm; Use two Guardian™ Sensor (3)s each connected to a Guardian™ Connect transmitter for approximately 7 days and undergo one Yellow Springs Instrument (YSI™) frequent sample testing (FST) (Day 1, 3-5, or 7).	Device: Guardian™ Sensor (3); Use two Guardian™ Sensor (3)s each connected to a Guardian™ Connect transmitter for approximately 7 days.

Outcome Measures

Primary Outcome Measures :

1. Percentage of Guardian™ Sensor (3) Values That Are Within 20% Agreement of YSI [ Time Frame: 168 Hours ]
   Percentage of Guardian™ Sensor (3) Values that are within 20% agreement of Yellow Springs Instrument (YSI) plasma glucose values (±20 mg/dL (1.1 mmol/L) when reference blood glucose (YSI) less than or equal to (≤) 80 mg/dL (4.4 mmol/L) ) during YSI frequent sampling testing (FST) days.
2. Consensus Error Grid Analysis of Mean Rate of Paired Sensor Values and YSI Values in Zone A+B [ Time Frame: 168 Hours ]
   A mean rate in Zone A+B of Consensus Error Grid between Guardian Sensor (3) values and YSI™* plasma glucose values during YSI™* FST days was evaluated. Consensus Error Grid (or Parkes error grid) compared the paired primary sensor and YSI reference glucose values. Zone A is defined in the Parkes error grid as the zone of "clinical accurate measurements with no effect on clinical action", Zone B as "altered clinical action with little or no effect on clinical outcome". Ideal situation is 100% in Zone A + B.
3. Clarke Error Grid Analysis of Mean Rate of Paired Sensor Values and YSI Values in Zone A+B [ Time Frame: 168 Hours ]
   A mean rate in Zone A+B of Clarke Error Grid between Guardian Sensor (3) values and YSI™* plasma glucose values during YSI™* FST days was evaluated. Clarke Error Grid compared the paired primary sensor and YSI reference glucose values. Zone A are "clinically accurate in that they would lead to clinically correct treatment decisions". Zone B "would lead to benign or no treatment". Ideal situation is 100% in Zone A + B.
4. Mean Absolute Relative Difference (MARD) [ Time Frame: 168 Hours ]
   Mean absolute relative difference (MARD) between Guardian Sensor (3) values and YSI™* plasma glucose values during YSI™* FST days was evaluated. MARD = Mean of ((Absolute difference of YSI reference and Sensor glucose values / YSI reference glucose values) * 100). Therefore, the unit of MARD is percentage (%). Note that results from multiple FST days were pooled together for reporting purpose.

Eligibility Criteria

• Ages Eligible for Study: 14 Years to 75 Years (Child, Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Subject is 14 - 75 years of age at time of screening
2. Subject has a clinical diagnosis of type 1 or 2 diabetes as determined via medical record or source documentation by an individual qualified to make a medical diagnosis
3. Subject has adequate venous access as assessed by investigator or appropriate staff
4. Subject is willing to follow the study procedures and willing to come to study visits

Exclusion Criteria:

1. Subject will not tolerate tape adhesive in the area of Guardian™ Sensor (3) placement as assessed by qualified individual.
2. Subject has any unresolved adverse skin condition in the area of study device or device placement (e.g., psoriasis, rash, Staphylococcus infection)
3. Subject is actively participating in an investigational study (drug or device) wherein they have received treatment from an investigational study (drug or device) in the last 2 weeks
4. Subject is female and has a positive pregnancy screening test
5. Females of child bearing age and who are sexually active should be excluded if they are not using a form of contraception deemed reliable by investigator
6. Subject is female and plans to become pregnant during the course of the study
7. Subject has a hematocrit (Hct) lower than the normal reference range
8. Subject may not be on the research staff of those performing this study

Contacts and Locations

Locations

China

The Seventh Medical Center of PLA General Hospital

Beijing, China, 100700

Sir Run Run Shaw Hospital

Hangzhou, China, 310016

Shanghai Sixth People's Hospital

Shanghai, China, 200233

Sponsors and Collaborators

Medtronic Diabetes

Investigators

• Principal Investigator: Jian Zhou, MD; Shanghai 6th People's Hospital
• Principal Investigator: Xiaofeng Lv, MD; Seventh Medical Center of PLA Army General Hospital
• Principal Investigator: Hong Li, MD; Sir Run Run Shaw Hospital

  Study Documents (Full-Text)

Documents provided by Medtronic Diabetes:

Study Protocol  [PDF] December 18, 2018

Statistical Analysis Plan  [PDF] December 14, 2019

More Information

• Responsible Party: Medtronic Diabetes
• ClinicalTrials.gov Identifier: NCT03710083
• Other Study ID Numbers: CIP320
• First Posted: October 17, 2018
• Results First Posted: August 21, 2020
• Last Update Posted: September 9, 2020
• Last Verified: August 2020

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: Yes
• Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by Medtronic Diabetes:

Diabetes Type I Type II